The controversy around technical standards for similar biotherapeutics: barriers to access and competition?

Saved in:
Bibliographic Details
Published inPharmacoepidemiology and drug safety Vol. 29; no. 11; pp. 1518 - 1522
Main Authors González, Claudia Patricia Vaca, Muñoz, Carolina Gómez
Format Journal Article
LanguageEnglish
Published Chichester, UK John Wiley & Sons, Inc 01.11.2020
Wiley Subscription Services, Inc
Subjects
biosimilar pharmaceuticals
developing countries
drug approval
drug substitution
drugs, generic
pharmacoepidemiology
World Health Organization
Online AccessGet full text

Cover

More Information
Bibliography:†
“Acknowledging that national authorities may use different terminologies when referring to similar biotherapeutic products” as established in Resolution WHA67.21. Some other terms will be used in this paper as synonyms of the term “biosimilar”: biogenerics or bio‐competitors, used in economics papers to refer to off‐patent drugs.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1053-8569
1099-1557
DOI:10.1002/pds.5100